Syncona Limited - Transaction in Own Shares
Syncona Limited
("Syncona" or the "Company")
Transaction in Own Shares
Syncona, a leading life science investor focused on creating, building and scaling a portfolio of global leaders in life science announces that, in accordance with the terms of its share buyback programme announced on
|
Date of purchase: |
|
|
Aggregate number of Ordinary Shares purchased: |
150,000 |
|
Lowest price paid per share (GBp): |
90.7559 |
|
Highest price paid per share (GBp): |
90.7559 |
|
Volume weighted average price paid per share (GBp): |
90.7559 |
The repurchased Ordinary Shares will be held by the Company in treasury. Following the purchase and settlement of these Ordinary Shares, the Company's issued ordinary share capital is 672,214,632 of which 54,118,637 Ordinary Shares will be held in treasury, which attract no voting rights. Therefore, the total voting rights in the Company will be 618,095,995. This figure for the total number of voting rights may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
In accordance with Article 5(1)(b) of Regulation (EU) No. 596/2014 which forms part of
Individual information:
|
Numbers of shares purchased |
Transaction price (pence per share) |
Time of transaction |
Venue |
|
150,000 |
90.7559 |
16:35.12 |
XLON |
For further information, please contact:
Syncona Ltd
Tel: +44 (0) 20 3981 7912
Deutsche Numis
Tel: +44 (0) 20 7260 1000
About Syncona
Syncona's purpose is to invest to extend and enhance human life. We do this by creating, building and scaling companies to deliver transformational treatments to patients in areas of high unmet need.
We aim to build and maintain a diversified portfolio of 20-25 globally leading life science businesses, across development stage, modality and therapeutic area, for the benefit of all our stakeholders. We focus on developing treatments that deliver patient impact by working in close partnership with world-class academic founders and experienced management teams. Our balance sheet underpins our strategy, enabling us to take a long-term view as we look to improve the lives of patients with no or poor treatment options, build sustainable life science companies and deliver strong risk-adjusted returns to shareholders.
Syncona Limited seeks to achieve returns over the long term. Investors should seek to ensure they understand the risks and opportunities of an investment in Syncona Limited, including the information in our published documentation, before investing.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
This content is published by Proactive Investors Limited and made available subject to the terms and conditions of use of its website (see Terms of Use).
Proactive Investors is a full-service financial newswire. We produce independent, objective financial journalism and do not provide personalised investment advice, act as a broker, or recommend specific securities to individual investors.
Financial content published on this Site is produced under the journalist exemption provided for in Article 20 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, and in accordance with FCA guidance at PERG 8.12. Where a communication is not otherwise exempt, it is issued or approved for distribution in the UK by Proactive Investors Limited.
All information used in the preparation of this communication has been compiled from publicly available sources that we believe to be reliable, however, we cannot, and do not, guarantee the accuracy or completeness of this communication.
This communication is intended for information purposes only and does not constitute investment advice, a personal recommendation, an offer, solicitation, or inducement to buy or sell any investment or financial product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
This communication has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Before entering into any transaction, investors should consider suitability for their individual circumstances and should read the relevant prospectus, term sheet, subscription agreement, information memorandum, prospectus or other offering document in full.
Past performance is not a reliable indicator of future results. The value of investments can fall as well as rise, and you may not recover the amount you invest.
This communication may contain information obtained from third parties, including credit ratings and financial data. Reproduction and distribution of third-party content in any form is prohibited except with the prior written consent of the relevant third party. Credit ratings are statements of opinion and should not be relied upon as investment advice.
FOR OUR FULL DISCLAIMER CLICK HERE